NCT04542382View on ClinicalTrials.gov

Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Rosuvastatin

"Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet."

DRUG

Rosuvastatin (Inhibitor arm)

"Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet."

DRUG

Eltrombopag

"Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet."

Trial Locations (1)

94143

Ucsf Ctsi Crc, San Francisco

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

University of California, San Francisco

OTHER

NCT04542382 - Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP) | Biotech Hunter | Biotech Hunter